Stem cell clinical trials have a certain gravitational pull for me as I’m always fascinated by them and since the new Cynata trial is moving forward, I recently did an interview their CEO, Dr. Ross A. Macdonald to find out more. PK: Cynata’s recently initiated clinical trial aims to treat GVHD as have other stem […]
Cynata stem cell trial update: CEO Ross Macdonald interview Read More »
By Cátia Bandeiras, PhD Student at University of Lisbon, Portugal and Massachusetts Institute of Technology. See tweets from the conference using #ISSCR2017 @apulgarita I just wrapped up my stay at the Annual Meeting of ISSCR 2017, which happened in Boston. I decided to take advantage of the fact that I am living in Boston at
Hunting for computational approaches for stem cells at ISSCR2017 Read More »
I received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks. I’ve started an on-line vote where you can vote once per day for
20 Nominees for Stem Cell Person of the Year 2016 Award Read More »
For quite a while there San Diego-based stem cell business Stemedica had a good run of publicity with reports of high-profile professional sports legends getting stem cells and the media reporting apparent good outcomes for stroke recovery, but more recent times have yielded some different publicity. An investigative report by KPBS reporter David Wagner raised some
Where does stem cell business Stemedica go from here after KPBS investigative report? Read More »
Today was the first part of the FDA’s 2-day meeting on stem cell draft guidances. It was a great meeting I thought. A few consistent themes and notable things emerged as raised by participants.
8 key arguments, take-homes on day 1 of FDA stem cell meeting Read More »
What can go wrong with unapproved stem cell clinic offerings? The answer including from presentations at the FDA today turns out to be very serious, negative results right here in the U.S. Thomas Albini, MD gave a talk entitled, “Severe Visual Loss After Intravitreal Injection of Autologous Adipose Tissue-derived Stem Cells for Age-related Macular Degeneration”.
Negative stem cell clinic outcomes include 3 blinded women Read More »
The second session at our CRISPR meeting was really powerful. As with other posts from the UC Davis CRISPR meeting, since I was taking notes on the fly during this session, this post is a stream of bits from the different talks, often trying to capture the essence of key questions or ideas as the speakers
UC Davis CRISPR Meeting Panel: A View from the Trenches on Human Disease Read More »
The number of people around the world being injected with stem cells every day has never been higher and the heterogeneous group of medical providers doing these procedures is also at or near its highest level ever. The cells used are also highly variable as are the procedures themselves, but most of these cells fall under the
Review of Centeno MSC safety paper: without controls, conclusions muted Read More »
A team at the University of Miami has launched a claimed first of its kind stem cell clinic trial for Alzheimer’s Disease (AD). The trial seems somewhat unique in using mesenchymal stem cells (MSC) for AD and is being run with biotech Longeveron. You can read more on the actual clinic trial including all the
New Stem Cell Clinic Trial for Alzheimer’s: Perspectives & Questions Read More »
Editor’s note: this is a guest post on the US stem cell environment. By Heather Main I moved to the San Diego from Australia in August 2015, and Paul asked me if I could write something on my first impressions of doing science in the US, as opposed to other countries I have worked/studied in
First impressions of the US stem cell environment from an Aussie Read More »